Atlas Trials

Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Clinical trial NCT06184360 · COMPLETED

Trial details

NCT number
NCT06184360
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Neovascular (Wet) Age-related Macular Degeneration
Start date
2022-05-31
Primary completion
2022-06-30
Enrollment
2079

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.